dr. powles on the 42-month follow-up data from the checkmate-214 trial in rcc
Published 4 years ago • 148 plays • Length 1:21Download video MP4
Download video MP3
Similar videos
-
1:06
dr. mckay discusses the checkmate-214 trial in rcc
-
1:33
dr. pal on the checkmate-214 and cabosun studies in rcc
-
1:21
dr. hammers on the long-term benefits of the checkmate-214 study in rcc
-
1:37
dr. amin on rationale for checkmate-214 trial in rcc
-
1:32
dr. pal compares checkmate-214 and cabosun trials in rcc
-
3:41
a physician faces stage iv #kidneycancer: his advice for you
-
1:27:40
#lwkc webinar - advancements in metastatic kidney cancer with professor thomas powles
-
14:05
checkmate-77t: perioperative nivolumab benefit for nsclc
-
1:58
dr. plimack on significance of checkmate-025 trial in rcc
-
1:38
dr. mcdermott on an analysis of the checkmate-214 study in rcc
-
13:10
asco gu24 special: prof. nizar tannir shares checkmate 214 results
-
1:54
checkmate 214 trial in rcc updates
-
1:14
dr. choueiri on significance of checkmate-025 study for rcc
-
1:17
dr. hammers on the checkmate-214 study for rcc
-
1:52
dr. powles on monitoring immunotherapy effects in patients with rcc
-
1:27
dr. hammers on nivolumab/ipilimumab data in rcc
-
1:42
dr. mcdermott on immotion150 trial in rcc
-
1:06
dr. agarwal on the checkmate-214 trial for kidney cancer
-
12:48
checkmate 214: 4-year follow-up and subgroup analysis of patients without nephrectomy
-
1:08
laurence albigès, md, phd, shares outcomes & updates from the checkmate 214 study in advanced rcc
-
2:30
checkmate 214 trial update
-
0:47
eric jonasch, md, on the 4 year checkmate-214 follow up investigating nivolumab ipilimumab